Shire Recalls Some Daytrana Patches

Some Daytrana medication used to treat ADHD has been recalled due to problems separating the patches from their packaging liners.

Thursday December 3rd - 1:08pm

Filed Under: Daytrana

Shire, the makers of the Daytrana patch, are stressing that today's product recall stems not from drug safety issues but rather from problems reported in separating the ADHD patch from its lining.

According to the Philadelphia Business Journal: "All Daytrana patches can continue to be used unless the release liner cannot be removed or the patches are damaged while being opened," Shire officials said. Daytrana is approved for the treatment of ADHD in children aged 6 to 12 years.

Read more about Shire's Daytrana recall.



FDA is warning that permanent loss of skin color may occur with use of the Daytrana patch (methylphenidate transdermal system) for Attention Deficit Hyperactivity Disorder (ADHD). FDA added a new warning to the drug label to describe this skin condition, which is known as chemical leukoderma. See the FDA Drug Safety Communication for more information.

Copyright © 1998 - 2015 New Hope Media LLC. All rights reserved. Your use of this site is governed by our Terms of Service and Privacy Policy.
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only. See additional information.
New Hope Media, 108 West 39th Street, Suite 805, New York, NY 10018